Dr Chapman, speaking at the IV International Workshop on Myeloma Genetics, Pharmacogenomics & Novel Therapeutics, discusses the findings of a large genome sequencing project and the future implications. The project found genes mutations found in other cancer appear in myeloma, meaning that existing treatments could possibly be used to treat multiple myeloma. Novel pathways have also been found providing new targets for potential treatment therapies.

The workshop was supported by an unrestricted medical education grant from the following companies; Celgene, Bristol Myers Squibb, Johnson and Johnson, Takeda Millennium, Novartis Oncology, Cephalon and Onyx Pharmaceuticals.